Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enwave Corp V.ENW

Alternate Symbol(s):  NWVCF

EnWave Corporation is an applied dehydration technology company. The Company’s principal business is the licensing of its intellectual property through royalty-bearing agreements and the design, construction, marketing, and sales of vacuum-microwave dehydration machinery for the food, cannabis and biomaterial industries. It has entered into 54 royalty-bearing commercial licenses with and sold REV equipment to a diverse portfolio of companies operating in over 23 different countries on five continents. It also operates REVworx, a toll processing facility located in Delta, British Columbia that offers vacuum-microwave contract manufacturing services. The REVworx facility houses both a batch 10 kilowatt (kW) and 60 kW continuous vacuum-microwave line to accelerate the commercialization of products made with the Company’s patented technology. The Company has two primary commercial scale technologies, nutraREV, a drum-based system, and quantaREV, a tray-based system.


TSXV:ENW - Post by User

Bullboard Posts
Comment by Commensenseon Apr 07, 2018 5:42pm
111 Views
Post# 27848204

RE:RE:EnWave’s Partner in Cannabis Space Takes Giant Leap

RE:RE:EnWave’s Partner in Cannabis Space Takes Giant LeapThe latest smallcaps report 10-may reported this on Sutro:
The powderREV machine for Sutro Biopharma, a pharmaceutical company based in San Francisco, is scheduled to be finished first. EnWave recently successfully conducted a pre-factory acceptance test. A factory acceptance test is currently ongoing. Once finished, this should trigger a go/no-go decision from Sutro to move the commercial scale REV machine from EnWave’s Vancouver facilities to Sutro’s San Francisco facilities for commercial startup in 2018.
If this REV machine is successful with the production of Sutro’s products, the company will immediately go into commercial production, as its ingredient does not require FDA approval. In that scenario, Sutro Biopharma would pay EnWave a royalty based on the production of its pharmaceutical ingredient.
Bullboard Posts